[Study on three patients with malignant glioma showing tumor reduction during maintenance therapy with MCNU].

Abstract

Tumor regression occurred in three of 19 patients (15.8%) with malignant glioma during maintenance therapy using MCNU. In two patients, the tumor reduced 5 and 8 months after the initial treatment, respectively. In the remaining patient, though the maintenance therapy was interrupted for a while and consequently the tumor size increased, readministration of MCNU reduced the tumor size two months later. Therefore, since the antitumor activity of MCNU against malignant glioma seems to require a certain time depending on the case, it is recommended that MCNU be given as maintenance therapy for at least half a year.

• Authors: K Kiya, T Uozumi, K Kurisu, T Mikami, K Sugiyama, S Monden, H Maeda, T Matsuoka, Y Matsuda, K Harada
• Journal: Gan to kagaku ryoho. Cancer & chemotherapy (Gan To Kagaku Ryoho) Vol. 20 Issue 8 Pg. 1083-6 (Jun 1993) ISSN: 0385-0684 [Print] Japan
• PMID: 8512339 (Publication Type: Case Reports, Journal Article)

Chemical References

• Antineoplastic Agents
• Nitrosourea Compounds
• ranimustine

Topics

• Adult
• Aged
• Antineoplastic Agents (therapeutic use)
• Astrocytoma (diagnostic imaging, drug therapy, pathology)
• Brain Neoplasms (diagnostic imaging, drug therapy, pathology)
• Child, Preschool
• Female
• Humans
• Male
• Nitrosourea Compounds (therapeutic use)
• Tomography, X-Ray Computed